Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 5, Pages 2398-2402Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01038-10
Keywords
-
Categories
Funding
- Grants-in-Aid for Scientific Research [23591485] Funding Source: KAKEN
Ask authors/readers for more resources
We evaluated the in vitro antianaerobic activity of razupenem (SMP-601, PTZ601), a new parenterally administered carbapenem, against 70 reference strains and 323 clinical isolates. Razupenem exhibited broad-spectrum activity against anaerobes, inhibiting most of the reference strains when used at a concentration of <= 1 mu g/ml. Furthermore, it exhibited strong activity, comparable to those of other carbapenems (meropenem and doripenem), against clinically isolated non-fragilis Bacteroides spp. (MIC(90)s of 2 mu g/ml), with MIC(90) values of 0.06, 0.03, and 0.5 mu g/ml against Prevotella spp., Porphyromonas spp., and Fusobacterium spp., respectively. Clinical isolates of anaerobic Gram-positive cocci, Eggerthella spp., and Clostridium spp. were highly susceptible to razupenem (MIC(90)s, 0.03 to 1 mu g/ml).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available